Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

China, already gaining speed in biotechnology, is looking to further accelerate novel drug development by reducing the time ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 million upfront for a preclinical GLP-1 drug the company hopes will have a ...

Over the past five years, licensing deals in the U.S. have averaged $84.8 billion. In China? Just $31.3 billion. Even with ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies aim to reduce.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...